Central Retinal Artery Occlusion and Eye Stroke Risk

Central retinal artery occlusion is a sudden blockage of the main artery feeding the inner layers of the retina, and it causes painless, near-complete vision loss in the affected eye within seconds to minutes. Often called an “eye stroke,” it shares the same underlying vascular disease as cerebral stroke and heart attack, which makes it far more than an eye problem. The retina tolerates lost blood flow for a remarkably short time before permanent damage sets in, so the gap between symptom onset and irreversible blindness is narrow and unforgiving.

What Happens Inside the Eye

The central retinal artery enters the eye through the optic nerve and branches across the inner retinal surface. When it becomes blocked, the inner retinal layers lose their oxygen supply almost immediately. The outer retina, which gets its oxygen from a separate set of vessels called the choroidal circulation, initially survives. That mismatch is what produces the classic appearance an eye doctor sees on examination: a pale, swollen inner retina everywhere except the very center of the macula, where the retina is thin enough for the choroidal blood supply to show through as a cherry-red spot against the surrounding whiteness.¹

Once blood flow stops, the inner retinal cells begin swelling. On imaging, this shows up as increased brightness in the inner retinal layers on optical coherence tomography (OCT), a scan that creates cross-sectional images of the retina.² The severity matters: in milder cases only the middle retinal layers opacify, while in severe cases the entire inner retina becomes swollen and bright. Over weeks and months, regardless of severity, the swollen tissue thins out as dead cells are cleared away, leaving a permanently atrophied inner retina.³

How Much Time the Retina Has

This is where the picture gets both grim and complicated. Animal experiments with complete occlusion of the artery show that energy reserves in retinal cells are drained within the first hour and a half, and severe, irreversible cell death is well underway by about four hours.⁴ Some researchers have argued that retinal infarction likely begins after as little as 12 to 15 minutes of complete blockage, which would explain why so many treatments fail even when started within a few hours.⁵

In real patients, though, the picture is messier. Most blockages are not perfectly complete. A clot may leave a trickle of blood getting through, or collateral vessels from the choroid may deliver a small amount of oxygen to at-risk tissue. This residual perfusion creates enormous person-to-person variability in how long the retina can survive. The same study that documented the 97-minute energy-depletion threshold in animals also noted that animals with pre-existing atherosclerosis actually tolerated longer periods of ischemia than healthy ones, possibly because chronic low-grade oxygen deprivation had conditioned their tissue. In humans, factors like the type of clot, the degree of residual flow, and a person’s vascular history all influence the timeline, making it impossible to set a single clock on irreversible damage.⁶

One useful biological marker is something called the cherry-red spot itself. Rather than relying on time alone, some researchers have proposed that the appearance of this spot signals complete oxygen starvation and irreversible infarction of the macular area. Before the cherry-red spot fully develops, reversal of the damage through increased oxygenation may still be possible, regardless of how many hours have passed.⁷

What Causes It

The vast majority of cases are “non-arteritic,” meaning the blockage comes from a blood clot or cholesterol plaque fragment, not from inflammation of the artery wall. This is the same type of embolism that causes ischemic stroke in the brain. A study comparing patients whose blockages were caused by visible emboli versus those without found that embolic cases tended to be younger (median age around 66) while non-embolic cases were older (median around 74) and had more advanced, hardened atherosclerosis in their carotid arteries.⁸ In the non-embolic group, stenosis of the carotid artery on the same side was more commonly high-grade, pointing to local atherosclerotic disease rather than a traveling clot as the culprit.

A much smaller but important subset of cases is caused by giant cell arteritis (GCA), an inflammatory condition of blood vessel walls that predominantly affects people over 50. GCA can cause CRAO along with several other sight-threatening conditions, including inflammation of the optic nerve’s blood supply.⁹ Distinguishing arteritic from non-arteritic CRAO matters enormously because GCA requires immediate high-dose steroid treatment to prevent the other eye from going blind. Anyone presenting with CRAO who is over 50, has a headache, jaw pain with chewing, scalp tenderness, or elevated inflammatory blood markers should be tested for GCA without delay.

The Cilioretinal Artery Advantage

Not everyone’s retinal blood supply follows the textbook diagram. Roughly a quarter to a third of people have a cilioretinal artery, an extra vessel that comes from the choroidal circulation instead of the central retinal artery. When it exists and happens to supply part of the macula, it can act as a lifeline during a CRAO because it remains open while the central retinal artery is blocked.

An older study of 107 CRAO cases found that about 26% had some degree of macular sparing from a patent cilioretinal artery, and those patients recovered variable but often meaningful vision depending on how much of the central retina the spare vessel covered. Patients without cilioretinal sparing rarely regained any useful vision at all.¹⁰ A more recent study confirmed that both initial and final visual acuity were significantly better in the cilioretinal-sparing group, though even in that group roughly four out of five eyes still ended up with poor vision.¹¹ Having a cilioretinal artery improves your odds, but “better than terrible” still leaves most people with serious vision loss.

Treatment Options and Their Limitations

The honest reality is that no treatment for CRAO has been proven to reliably restore vision in large, rigorous trials. A long list of approaches has been tried over the decades: ocular massage, medications to lower eye pressure, inhaled carbon-dioxide-oxygen mixtures, blood vessel dilators, and paracentesis (draining a small amount of fluid from the front of the eye). None of these have been shown to change the natural course of the disease in a definitive way.¹²

That said, ocular massage remains commonly attempted in emergency settings because it is simple, fast, and carries minimal risk. A recent case series using real-time OCT angiography to monitor the retina during massage showed improvements in blood vessel density and visual acuity.¹³ The idea is that rhythmic pressure on the eyeball can dislodge a clot or push it further downstream where it blocks a smaller area. It sometimes works, but case series are not the same as controlled trials, and most experts view massage as worth trying without expecting much.

Hyperbaric Oxygen Therapy

Hyperbaric oxygen therapy (HBOT) works on a different principle. Instead of trying to remove the clot, it floods the bloodstream with oxygen at high pressures, allowing oxygen to diffuse from the still-functioning choroidal vessels into the starving inner retina. The Undersea and Hyperbaric Medical Society recommends evaluation for HBOT within 24 hours of symptom onset.¹⁴

A study comparing HBOT-treated patients (all treated within seven days of symptom onset) to untreated controls found a statistically meaningful improvement in visual acuity in the treated group over six months, while the untreated group’s vision stayed flat.¹⁵ The treated group also showed preservation of retinal layer thickness, especially in the outer retina, suggesting that HBOT helped keep tissue alive that would otherwise have atrophied. These are encouraging results, but the evidence base still consists mostly of observational studies rather than large randomized trials, and access to hyperbaric chambers within the critical window remains a practical barrier in many locations.

Thrombolysis: Breaking Up the Clot Directly

Because CRAO and ischemic stroke share the same basic mechanism, researchers have naturally tried clot-dissolving drugs. These have been delivered in two ways: through a standard IV line (systemic thrombolysis) or through a catheter threaded directly into the ophthalmic artery (intra-arterial thrombolysis, or IAT).

The only randomized controlled trial of intravenous tPA for CRAO was small and sobering. Two of eight patients in the treatment group showed visual improvement at one week, but neither maintained the improvement at six months. One patient had an intracranial hemorrhage.¹⁶

Intra-arterial thrombolysis has been studied more extensively, though mostly in uncontrolled case series. Combining data across studies, about 3% of IAT patients experienced major complications including intracranial bleeding, stroke, and transient ischemic attacks.¹⁷ The one major randomized trial that directly compared IAT to conservative treatment (the EAGLE trial) was stopped early by its safety monitoring board. The two arms had similar rates of visual improvement, but the IAT group had substantially more adverse events, roughly 37% compared to about 4% in the conservative group.¹⁸ That trial effectively dampened enthusiasm for routine IAT, though some interventional neuroradiologists still offer it in selected cases where the risk-benefit calculation favors aggression, particularly in younger patients with recent symptom onset and no cherry-red spot yet.

CRAO as a Warning Sign for Stroke and Heart Attack

Perhaps the most important thing about CRAO, beyond the immediate threat to the eye, is what it signals about the rest of the cardiovascular system. When a clot blocks the retinal artery, it is often the first visible sign of widespread vascular disease that could just as easily produce a stroke or heart attack next.

A prospective study that performed a standardized cardiovascular workup on all CRAO patients found previously undiagnosed vascular risk factors in 78% of them. The single most important finding was narrowing of the carotid artery on the same side as the affected eye.¹⁹ The American Heart Association has explicitly called for urgent screening and treatment of vascular risk factors in CRAO patients.²⁰

And some patients are already having a stroke at the same time as their eye event without knowing it. Brain MRI studies of CRAO patients have found acute, silent cerebral infarctions in roughly 18 to 25% of cases, most of which produce no neurological symptoms at the time.²¹ The rate of coincident brain infarction climbs with age, reaching about 30% in patients over 70.²² This is why many stroke centers now treat acute CRAO with the same urgency as a transient ischemic attack, admitting patients for neuroimaging, carotid ultrasound, and cardiac monitoring.

The long-term numbers underline the stakes. A large study tracking outcomes over years found that within five years of a retinal artery occlusion event, roughly 23% of patients had died, about 11% had suffered a stroke, and 6% had a heart attack. By ten years, the death rate had climbed to nearly 58%.²³ These are not eye statistics; they are cardiovascular statistics. CRAO patients carry roughly triple the risk of heart attack and stroke compared to age-matched people without the condition.²⁴

Long-Term Eye Complications

Even after the acute crisis passes, the damaged eye can develop new problems. When the inner retina is starved of oxygen, it sometimes responds weeks later by growing abnormal new blood vessels, a process called neovascularization. These fragile vessels can appear on the iris, the optic disc, or both, and when they grow into the drainage angle of the eye they block fluid outflow and cause a painful, blinding rise in eye pressure known as neovascular glaucoma.

Studies have found that somewhere between 15 and 18% of CRAO eyes develop neovascularization, with most cases appearing within the first one to four months.²⁵ ²⁶ In one series, the average time to detection was about 30 days, though some cases appeared as late as four months after the initial event. Of those who developed neovascularization, the vast majority progressed to neovascular glaucoma, which requires aggressive treatment with laser, medications, or both.²⁷ This is a strong argument for regular follow-up eye exams in the months after a CRAO, even when the vision in that eye is already poor and the patient may be tempted to skip appointments.

Neuroprotection and What Comes Next

The frustrating treatment landscape has pushed researchers to borrow from the stroke world in a different way: neuroprotection. The idea is that even if you cannot dissolve a clot quickly enough, you might slow down the rate at which retinal cells die, buying time for either spontaneous reperfusion or a delayed intervention to work. One experimental drug, a compound called KUS121 that helps retinal neurons conserve their energy stores, showed promising early results in a small first-in-humans trial. All nine patients treated with intravitreal injection showed significant improvement in visual acuity, visual field scores, and retinal sensitivity.²⁸ It is a tiny, uncontrolled trial and should be read with appropriate caution, but the concept of combining neuroprotection with clot-busting therapy to extend the treatment window is actively being explored.²⁹

The broader trajectory of CRAO research is toward treating it like a true medical emergency in the same infrastructure that handles stroke. More hospitals are developing “eye stroke” protocols that route patients directly to emergency departments equipped with neuroimaging, vascular evaluation, and access to hyperbaric oxygen or interventional neuroradiology, rather than sending them to an outpatient ophthalmology clinic the next day. Whether that shift in logistics will translate into better visual outcomes depends on whether any of the current or emerging treatments can beat the retina’s extremely short tolerance for ischemia. For now, the strongest case for emergency-level care is not about saving the eye alone; it is about catching the systemic vascular disease that put the eye at risk in the first place and preventing the stroke or heart attack that too often follows.